Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000230793 | SCV000286256 | uncertain significance | Long QT syndrome | 2023-03-07 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 238587). This variant has not been reported in the literature in individuals affected with ANK2-related conditions. This variant is present in population databases (rs758054052, gnomAD 0.01%). This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 2369 of the ANK2 protein (p.Val2369Phe). |
| Agnes Ginges Centre for Molecular Cardiology, |
RCV000853461 | SCV000996372 | uncertain significance | Primary dilated cardiomyopathy | 2017-06-20 | criteria provided, single submitter | research | The ANK2 Val2369 variant has been reported previously in 1 Long QT (Invitae, ClinVar: SCV000286256.1) and 1 HCM patient (Lopes, et al., 2015). We identified this variant in a DCM proband that was diagnosed after suffering a cardiac arrest. The probands sibling passed away from cardiomyopathy and another family died suddenly however segregation was not possible. The variant is present in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/) at an allele frequency > 0.00004, which is greater then expected for the disease. In silico models, SIFT, MutationTaster and PolyPhen-2 predict the change to be benign. In summary, the variant is present in the general population at a frequency higher then expected for the disease and in silico tools predict this variant to be benign, therefore we classify ANK2 Val2369Phe as a variant of 'uncertain significance'. |
| Gene |
RCV001785525 | SCV002028069 | uncertain significance | not provided | 2021-11-12 | criteria provided, single submitter | clinical testing | Identified in patients with HCM in the published literature (Lopes et al., 2015); In silico analysis supports that this missense variant does not alter protein structure/function; Located in exon 38, which is reported as being expressed in a brain-specific transcript (Otto et al, 1991; Cunha et al, 2008; Wu et al, 2015); Reported in ClinVar as a variant of uncertain significance (ClinVar Variant ID# 238587; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 25351510) |
| Ambry Genetics | RCV002365186 | SCV002662628 | likely benign | Cardiovascular phenotype | 2024-02-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Fulgent Genetics, |
RCV002478848 | SCV002792935 | uncertain significance | Cardiac arrhythmia, ankyrin-B-related | 2022-01-08 | criteria provided, single submitter | clinical testing |